Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Aaron Parsley

Physician Assistant Little Rock, AR Physician Assistant

NPI 1356581151 CMS profile 10667452

11415 Executive Center Dr, Little Rock, AR 72211

Open in the dashboard

General payments

$8,592

605 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aaron Parsley of Little Rock, AR is reported in the CMS Open Payments database as having received $8,592 across 605 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,486 96
2024 General $2,056 139
2023 General $1,810 125
2022 General $1,886 138
2021 General $1,354 107

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aaron Parsley
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Aaron Parsley were reported at $1,486. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Aaron Parsley Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,354 $132 $37–$438 $132
2022 $1,886 $155 $48–$522 $149
2023 $1,810 $167 $52–$557 $160
2024 $2,056 $178 $55–$600 $164
2025 $1,486 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,821 127 payments
  2. GlaxoSmithKline, LLC. $793 61 payments
  3. Lilly USA, LLC $687 57 payments
  4. Pfizer Inc. $675 53 payments
  5. Amgen Inc. $579 42 payments
  6. AstraZeneca Pharmaceuticals LP $529 24 payments
  7. Novo Nordisk Inc $383 27 payments
  8. Janssen Pharmaceuticals, Inc $311 22 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $222 17 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $212 17 payments
  11. Other $2,379 158 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,592 605 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $681 32 payments
  2. UBRELVY $625 40 payments
  3. TRELEGY ELLIPTA $624 50 payments
  4. VRAYLAR $586 57 payments
  5. NURTEC ODT Pain $469 39 payments
  6. JARDIANCE $335 28 payments
  7. AIRSUPRA $318 10 payments
  8. NURTEC ODT Primary Care $290 22 payments
  9. FARXIGA $284 8 payments
  10. ZAVZPRET $284 23 payments
  11. Other $7,039 485 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

912

Median for Physician Assistant: 241

Drug cost

$14,869

Median for Physician Assistant: $4,110

Branded share of claims

17.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Paxlovid Nirmatrelvir/Ritonavir Brand 27 $5,646
Cefdinir Generic 185 $3,403
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 44 $907
Doxycycline Hyclate Generic 93 $822
Albuterol Sulfate Hfa Albuterol Sulfate Brand 20 $630
Ipratropium Bromide Generic 27 $625
Diclofenac Sodium Generic 31 $445
Prednisone Generic 166 $432
Mupirocin Generic 29 $217
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 19 $181

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$30,551

Of which drugs: $359

Medicare patients

404

Average age 73

Services billed

1,916

249 women, 155 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 32%
Depression 31%
Diabetes 28%
Chronic kidney disease 22%
Atrial fibrillation 21%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 75 778 $64
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 68 $42
Injection, ketorolac tromethamine, per 15 mg J1885 Office 12 56 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $156
  • Boehringer Ingelheim Pharmaceuticals, Inc. $31
$187 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $147
$147 — —
VRAYLAR
  • AbbVie, Inc. $137
$137 — —
UBRELVY
  • AbbVie, Inc. $135
$135 — —
QULIPTA
  • AbbVie, Inc. $135
$135 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

605 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record